MGC Pharmaceuticals Ltd.

Launch of ZAM - Medical data App

06 July 2022

ASX, LSE: MXC

Key Highlights:

·       MGC Pharma, in collaboration with software development company, Caba Tech, is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors.

·       ZAM will enable patients to access medical support wherever they are in the world, monitoring drug use and its effects, as well as allowing patients to contact a doctor and get a prescription.

·       The launch will take place across two phases: the first being a "closed launch"  to collect data from 100 patients enrolled through MGC Pharma's Australian tele-health business MCC.

·       The second phase release details will be announced in Q3, 2022.

·       In time, the App and it associated Artificial Intelligence (AI) machine learning capability, will help predict potential intra-treatment side effects, and generate statistics that measure aggregate and holistic treatment outcomes.

·       Through its AI learning and functionality, the App offers the possibility of personalising medication, not just with cannabis-based products, but with all treatments and pharmaceutical drugs. The integration of this learning algorithm is revolutionary in the sector, setting the development far ahead of market peers, providing tailored medical information, alongside their health practitioner, increasing the efficiency of the healthcare system.

·       The App will be introduced to the 4,000 patients, who are currently using MGC's products when publicly released in Q3, which will increase as it is rolled out across different networks throughout the year.

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the upcoming launch of a data collection App and machine learning algorithm, ZAM, developed in conjunction with software development company Caba Tech.

The Application, which is scheduled to be available from App stores in Q3 2022, following successful completion of the certification process, will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will provide users with a more complete understanding of their health and treatment impact. The App will not only provide patients with instructions on how and when to take medication (per their medical practitioners advice), but will also measure treatment progress, and have the ability for a qualified doctor to prescribe alternative medication following a consultation.

Once the initial phase of data collection is underway, the App's AI  or machine learning will begin. The algorithm will use data collected from the App, in addition to results from academic and clinical studies, to predict potential conflicting side effects from multiple treatments, as well as allowing users to order existing prescriptions, and provide the App user's practitioner with a comprehensive set of data on treatment and medical history. ZAM will be accessible across the globe, making the App more accessible than any doctor.

The Application will have some immediate benefits to MGC Pharma, as. It will enable improved data collection from patients enrolled in clinical trials, and taking MGC Pharma products, which will help improve the accuracy of our clinical trials and dosing of our products,  

In time, the statistical database created by ZAM will also be useful to a range of organisations, such as pharmaceutical businesses, insurers and other healthcare providers, which will provide the Company with an opportunity to commercialise both the App and data.

ZAM is a joint venture between Caba Tech and MGC Pharma, with MGC Pharma currently in discussions with Caba Tech to acquire a 40% stake in the application, leaving Caba Tech responsible for the App development.

Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: "It has been clear to us for some time that used properly, AI has the ability to transform the pharmaceutical industry, and improve outcomes for patients. Our work with Caba Tech has produced an App which has broad ranging implications for the health sector. This App will serve as an 'online doctor', both collecting data and learning from it to predict conflicts in treatments, increasing efficiency for medical practitioners."

Our conversations across the medical research industry and with patients have shown there is a real need for this App, and we truly believe that it can revolutionise the delivery of medical services for people globally."

Alessandra-Manuela Cadavid-Doubinina CEO of Caba Tech, commented: "We believe that apps like ZAM are able to change the way people take medication and discuss the effects of their treatment with their practitioners. The app will help clinical research teams to receive live and high-quality data on their patients, which will enable drug research to be as precise as possible. The aim of the AI is to help doctors make fast decisions in patient treatment with data collected in 40 different languages and 2 million different recaches in less than 2 minutes, which serves as the gate to collective intelligence."

--Ends--

Authorised for release by the Chairman, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America, and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far, therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

About Caba Tech

Caba Tech (Caba) is an international research and development company specialising in artificial intelligence, big data structure, web3, software and web development. Over the past 4 years Caba has released over 70 projects in diverse fields. The Company's mission is to create positive technology in fields such as finance, sustainability, medicine, and education.

Caba Tech covers the full spectrum of the development pipeline starting with technical analysis, all the way to through to market strategy. Caba gives a strong accent on brand and design. All projects released by Caba have one of the best UX UI experiences and are designed to meet the goals of the project, as well as make it as simple to use as possible to the users.

ZAM has been a project that was in development for over 18 months, with theApp aimed to change the world of patient/ doctor relationships and give the ability of personalised medication, by using existing data and ZAM's artificial intelligence functionality to help doctors adjust medication for each patient's needs.

Website: caba.tech

LinkedIn: CABA tech

Instagram: @caba.tech